SCM4 Antibody

What is SCML4 and what cellular functions is it associated with?

SCML4 (sex comb on midleg-like 4) is a protein originally identified in Drosophila with human and mouse homologs. The full name is "sex comb on midleg-like 4 (Drosophila)" with a calculated molecular weight of 45 kDa (414 amino acids), though it typically appears at 50-60 kDa in experimental observations . SCML4 is encoded by the SCML4 gene (Gene ID: 256380) and is part of the Polycomb group protein family that plays roles in developmental regulation and epigenetic modifications. The protein has been detected in multiple tissues including liver and is expressed in cell lines such as A375 and HEK-293 .

What applications can SCML4 antibody be validated for in research protocols?

SCML4 antibody (25439-1-AP) has been validated for several research applications with varying degrees of optimization:

The antibody should be titrated in each specific testing system to obtain optimal results as sensitivity may vary depending on experimental conditions and sample types .

What species reactivity has been confirmed for SCML4 antibody?

Current validation data confirms that the SCML4 antibody (25439-1-AP) demonstrates specific reactivity with:

The antibody was developed using a SCML4 fusion protein (Ag22157) as the immunogen, which contributes to its specificity profile .

What is the optimal sample preparation protocol for Western blot detection of SCML4?

When preparing samples for Western blot detection of SCML4, researchers should follow this methodological approach:

• Harvest cells at 80-90% confluence or tissue samples (preferably fresh)

• Lyse samples in RIPA buffer containing protease inhibitors (PMSF 1mM, aprotinin 10μg/ml, leupeptin 10μg/ml)

• Homogenize tissues using mechanical disruption followed by sonication (3-5 pulses of 10 seconds each)

• Centrifuge lysates at 14,000g for 15 minutes at 4°C and collect supernatant

• Determine protein concentration using Bradford or BCA assay

• Prepare 20-50μg of protein per lane in Laemmli buffer with reducing agent

• Heat samples at 95°C for 5 minutes before loading

For SCML4 detection specifically, avoid excessive heating which may cause protein aggregation, and use fresh samples when possible as the protein may be sensitive to freeze-thaw cycles .

Why is there a discrepancy between calculated (45 kDa) and observed (50-60 kDa) molecular weight of SCML4?

The discrepancy between the calculated molecular weight (45 kDa) and the observed molecular weight (50-60 kDa) of SCML4 in experimental conditions can be attributed to several factors:

• Post-translational modifications: SCML4 may undergo glycosylation, phosphorylation, or other modifications that increase its apparent molecular weight

• Protein structure: The tertiary structure of some proteins can affect their migration in SDS-PAGE

• Splice variants: Alternative splicing may result in protein isoforms with different molecular weights

• Technical factors: Gel concentration, running buffer composition, and voltage can all affect protein migration

Researchers should validate the observed band using positive controls and knockdown/knockout samples to confirm specificity. This molecular weight discrepancy is documented in the technical information for the antibody and represents a known characteristic of the protein rather than an experimental error .

What validation controls are essential when using SCML4 antibody in novel experimental contexts?

When implementing SCML4 antibody in new experimental systems, comprehensive validation is critical. Essential controls include:

• Positive controls: Include samples with known SCML4 expression (mouse liver tissue, A375 cells, or HEK-293 cells)

• Negative controls:

  • Primary antibody omission

  • Non-specific IgG control at matching concentration

  • SCML4 knockdown/knockout samples (if available)

• Peptide competition assay: Pre-incubate antibody with excess immunizing peptide to demonstrate binding specificity

• Multiple antibody validation: If possible, confirm results with a second SCML4 antibody targeting a different epitope

• Cross-reactivity assessment: Test antibody against samples from species not listed in reactivity data

• Method-specific controls: For immunohistochemistry, include tissue-specific controls; for immunoprecipitation, verify with reverse IP

Proper validation not only ensures experimental rigor but also helps troubleshoot potential issues when applying this antibody to new cell types or experimental conditions not previously tested .

What troubleshooting approaches should be employed when SCML4 antibody produces weak or non-specific signals?

When encountering weak or non-specific signals with SCML4 antibody, implement this systematic troubleshooting approach:

For weak signals:

• Optimize antibody concentration: Test a range of dilutions (1:250 to 1:2000) to identify optimal concentration

• Increase protein loading: Load 50-70μg per lane instead of standard 20-30μg

• Extend primary antibody incubation: Incubate overnight at 4°C instead of 1-2 hours at room temperature

• Enhance detection sensitivity: Use high-sensitivity ECL substrates or increase exposure time

• Modify blocking conditions: Test different blocking agents (5% BSA vs. 5% milk) as SCML4 detection may be affected by specific blocking reagents

For non-specific signals:

• Increase washing duration and frequency: Perform 5 washes of 5-10 minutes each with 0.1% TBST

• Optimize blocking: Increase blocking time to 2 hours at room temperature

• Reduce primary antibody concentration: Use more dilute antibody (1:1000 to 1:2000)

• Pre-adsorb antibody: Incubate with non-target tissue lysate to remove cross-reactive antibodies

• Use gradient gels: Employ 4-12% gradient gels for better protein separation

Additionally, the storage buffer (PBS with 0.02% sodium azide and 50% glycerol, pH 7.3) may affect antibody performance if diluted improperly. Ensure proper buffer conditions and antibody handling to maintain optimal activity .

How can SCML4 antibody be integrated into multi-omics research approaches?

Integrating SCML4 antibody into multi-omics research requires strategic experimental design:

• Proteomics integration:

  • Use SCML4 antibody for immunoprecipitation followed by mass spectrometry to identify interaction partners

  • Combine with phospho-specific antibodies to characterize post-translational modification states

  • Implement protein array technologies with SCML4 antibody to assess binding partners

• Genomics-proteomics correlation:

  • Correlate SCML4 protein levels (detected by Western blot) with RNA-seq data to identify post-transcriptional regulation

  • Use ChIP-seq with SCML4 antibody to map genomic binding sites if SCML4 has DNA-binding activity

• Spatial biology approaches:

  • Combine immunofluorescence using SCML4 antibody with single-cell RNA-seq data for spatial context

  • Implement imaging mass cytometry with SCML4 antibody for tissue-level protein localization

• Functional validation:

  • Use SCML4 antibody to validate protein knockdown efficiency in CRISPR or RNAi experiments

  • Implement antibody in functional assays to correlate SCML4 levels with phenotypic outcomes

When designing such integrated approaches, researchers should consider the antibody's specificity profile (human and mouse reactivity) and validated applications (primarily Western blot) to ensure technical feasibility .

What are the optimal storage and handling conditions to maintain SCML4 antibody activity?

To maintain optimal activity of SCML4 antibody (25439-1-AP), follow these research-validated storage and handling protocols:

For handling during experiments:

• Thaw antibody completely but gently before use

• Mix by gentle inversion, avoid vortexing which can denature antibody proteins

• Keep on ice during experiment setup

• Return to -20°C promptly after use

• Avoid repeated freeze-thaw cycles which significantly reduce antibody performance

• For diluted working solutions, prepare fresh and use within 24 hours

These conditions ensure maintenance of antibody binding capacity and specificity across multiple experimental applications .

How should researchers design experiments to investigate SCML4 across different cell lines and tissues?

When investigating SCML4 expression across diverse biological samples, implement this methodological framework:

• Initial screening approach:

  • Begin with validated positive samples (mouse liver tissue, A375 cells, HEK-293 cells)

  • Include protein loading controls (β-actin, GAPDH) for normalization

  • Use standardized lysis buffer and protein extraction protocol across all samples

• Optimization for tissue-specific detection:

  • For tissue samples: Use tissue-specific extraction buffers with appropriate protease inhibitors

  • For highly fibrous tissues: Extend homogenization time and consider adding collagenase treatment

  • For lipid-rich tissues: Include additional detergents or delipidation steps

• Experimental design for comparative studies:

  • Use consistent protein amounts (30-50μg) across all samples

  • Process all samples in parallel to minimize experimental variation

  • Include biological replicates (minimum n=3) for statistical validity

  • Consider running samples on the same gel when possible for direct comparison

• Quantification methodology:

  • Normalize SCML4 signals to loading controls

  • Use digital image analysis software to quantify band intensity

  • Apply appropriate statistical tests for comparative analysis

• Validation strategies:

  • Confirm key findings with orthogonal methods (qPCR, immunofluorescence)

  • For novel tissue/cell types, validate with siRNA knockdown experiments

This systematic approach ensures reproducible detection of SCML4 across diverse biological contexts while maintaining experimental rigor .

How can SCML4 antibody be applied in therapeutic target validation studies?

For researchers investigating SCML4 as a potential therapeutic target, the antibody can be methodically applied through the following research workflow:

• Target expression profiling:

  • Use Western blot with SCML4 antibody to quantify expression levels across:

    • Normal vs. disease tissue samples

    • Drug-sensitive vs. resistant cell lines

    • Different stages of disease progression

• Functional validation approaches:

  • Combine antibody-based detection with:

    • CRISPR/Cas9 knockout studies (using antibody to confirm protein depletion)

    • siRNA knockdown validation (using antibody at 1:500 dilution for Western blot)

    • Overexpression studies (comparing endogenous vs. exogenous protein levels)

• Mechanism elucidation:

  • Immunoprecipitation with SCML4 antibody followed by proteomic analysis

  • Co-immunoprecipitation to identify therapeutic-relevant interaction partners

  • Phospho-specific analysis to identify activation-dependent modification sites

• Pharmacodynamic marker development:

  • Develop SCML4 quantification methods for:

    • Tissue biopsies before/after experimental treatment

    • Circulating tumor cells or exosomes

    • Patient-derived xenograft models

• Companion diagnostic potential:

  • Validate SCML4 antibody for potential diagnostic applications:

    • Tissue microarray analysis correlating expression with treatment response

    • Multiplexed imaging with other biomarkers of therapeutic response

When designing such validation studies, researchers should ensure appropriate controls and validation steps are incorporated to maintain scientific rigor and reproducibility .

What are the methodological considerations when using SCML4 antibody in co-immunoprecipitation experiments?

When applying SCML4 antibody in co-immunoprecipitation (co-IP) experiments to investigate protein interactions, researchers should follow this methodological framework:

• Lysis buffer optimization:

  • Use mild, non-denaturing lysis buffers to preserve protein-protein interactions

  • Recommended starting composition: 50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate

  • Include appropriate protease and phosphatase inhibitors

  • Avoid harsh detergents (SDS) that may disrupt protein complexes

• Antibody binding optimization:

  • Pre-clear lysate with protein A/G beads to reduce non-specific binding

  • Determine optimal antibody amount: start with 2-5μg per 500μg of protein lysate

  • For SCML4 antibody specifically, allow overnight binding at 4°C with gentle rotation

• Control implementation:

  • Include IgG isotype control (rabbit IgG) processed identically to SCML4 antibody samples

  • Include input sample (5-10% of starting material) as reference

  • Consider including SCML4-depleted samples as negative controls

• Washing protocol development:

  • Optimize wash stringency: begin with 4-5 washes using lysis buffer

  • If background is high, increase wash stringency by adding salt (up to 300mM NaCl)

  • If signal is lost, reduce stringency by decreasing salt or detergent concentrations

• Elution and detection optimization:

  • For Western blot analysis of co-IP samples, use 40-50% of IP material per lane

  • Consider native elution for functional studies of co-precipitated complexes

  • For mass spectrometry analysis, perform specialized elution to minimize antibody contamination

This methodological approach maximizes the likelihood of successful co-IP experiments while maintaining specificity and sensitivity when using SCML4 antibody to study protein-protein interactions .

How should researchers interpret conflicting results between SCML4 antibody data and other detection methods?

When encountering discrepancies between SCML4 antibody results and alternative detection methods, implement this systematic analytical approach:

• Methodological comparison analysis:

  • Compare the detection principles of each method:

    • Antibody detection (epitope-specific) vs. mass spectrometry (peptide-specific)

    • Protein detection (SCML4 antibody) vs. mRNA detection (qPCR, RNA-seq)

  • Evaluate whether differences reflect post-transcriptional regulation

• Technical validation steps:

  • Confirm antibody specificity through:

    • Knockout/knockdown controls

    • Peptide competition assays

    • Testing multiple antibodies targeting different SCML4 epitopes

  • Assess whether discrepancies depend on sample preparation methods

• Biological validation approaches:

  • Investigate potential biological explanations:

    • Protein stability and half-life effects

    • Post-translational modifications altering epitope accessibility

    • Splice variants detected differently by various methods

    • Subcellular localization affecting detection

• Reconciliation strategy:

  • Design experiments that directly address the specific discrepancy

  • Use orthogonal methods to validate key findings

  • Consider the biological question being addressed to determine which method provides most relevant data

• Reporting recommendations:

  • Transparently report all discrepancies in research publications

  • Provide methodological details that might explain differences

  • Present data from multiple detection methods when available

What methodological approaches can improve reproducibility when using SCML4 antibody across different research laboratories?

To enhance inter-laboratory reproducibility when using SCML4 antibody, implement these standardized methodological practices:

• Detailed antibody reporting:

  • Document complete antibody information in all protocols and publications:

    • Catalog number (25439-1-AP)

    • Lot number (to track potential lot-to-lot variations)

    • Host species and isotype (Rabbit IgG)

    • Clonality (Polyclonal)

    • RRID identifier (AB_2880081)

• Standardized protocol development:

  • Create detailed step-by-step protocols including:

    • Exact buffer compositions with pH values

    • Precise antibody dilutions (1:500-1:1000 for WB)

    • Incubation times and temperatures

    • Sample preparation methods

    • Equipment settings (e.g., imaging parameters)

• Validation approach harmonization:

  • Establish common validation criteria:

    • Use shared positive controls (mouse liver tissue, HEK-293 cells, A375 cells)

    • Implement consistent negative controls

    • Adopt standardized methods for quantifying signal intensity

• Reference material exchange:

  • Share validated lysates or samples between laboratories

  • Develop common standard curves for quantitative applications

  • Create repository of expected results for reference

• Collaborative quality control:

  • Implement regular cross-laboratory testing of the same samples

  • Document environmental conditions that may affect results

  • Create troubleshooting decision trees for common problems

This methodological framework significantly enhances reproducibility and facilitates meaningful comparison of SCML4 antibody data generated across different research settings .

How can SCML4 antibody be adapted for emerging single-cell protein detection technologies?

Integrating SCML4 antibody into cutting-edge single-cell protein analysis requires specific methodological adaptations:

• Single-cell Western blot adaptations:

  • Optimize antibody concentration: Start with 5-10× higher concentration than conventional Western blot

  • Extend incubation time: 12-24 hours at 4°C to compensate for reduced protein amount

  • Implement signal amplification: Use tyramide signal amplification or similar enhancement methods

  • Validate specificity in single-cell format with known SCML4-expressing cell lines (A375, HEK-293)

• Mass cytometry (CyTOF) implementation:

  • Metal conjugation protocol:

    • Purify antibody using protein A/G columns

    • Conjugate with rare earth metals using validated chelation chemistry

    • Test conjugates at multiple concentrations (1:50, 1:100, 1:200)

  • Validate metal-conjugated antibody against unconjugated version using conventional methods

• Microfluidic-based protein assay optimization:

  • For droplet-based single-cell proteomics:

    • Optimize antibody concentration within microfluidic environment

    • Test sensitivity using serial dilutions of cell lysates

    • Implement parallel analysis with validated cell lines

• Spatial proteomics integration:

  • For CODEX or multiplexed imaging:

    • Test compatibility with tissue fixation protocols

    • Optimize antibody-oligonucleotide conjugation if required

    • Validate spatial distribution patterns against conventional immunofluorescence

• Single-cell proteogenomic approaches:

  • For CITE-seq or similar technologies:

    • Develop and validate antibody-oligonucleotide conjugates

    • Optimize concentrations for multiplexed applications

    • Correlate protein detection with transcriptomic data

These methodological adaptations enable researchers to leverage SCML4 antibody in emerging single-cell technologies while maintaining specificity and sensitivity .

What considerations should guide researchers in selecting between different anti-SCML4 antibodies for specialized applications?

When selecting among different anti-SCML4 antibodies for specialized research applications, implement this methodological decision framework:

• Epitope mapping assessment:

  • Determine the specific epitope recognized by each antibody

  • Evaluate epitope conservation across species of interest

  • Consider epitope accessibility in different experimental conditions:

    • Native vs. denatured applications

    • Fixed vs. live-cell applications

    • Sensitivity to post-translational modifications

• Application-specific validation:

  • For immunohistochemistry: Prioritize antibodies validated in fixed tissues

  • For immunoprecipitation: Select antibodies that recognize native protein conformations

  • For proximity labeling techniques: Evaluate antibody performance in crowded molecular environments

  • For super-resolution microscopy: Assess antibody specificity at nanoscale resolution

• Technical specification comparison:

  • Compare antibody formats:

    • Full IgG vs. Fab fragments vs. single-domain antibodies

    • Polyclonal (broader epitope recognition) vs. monoclonal (higher specificity)

    • Host species compatibility with experimental systems

  • Assess detection sensitivity requirements:

    • Limit of detection needed for the application

    • Signal-to-noise ratio in relevant sample types

• Experimental validation strategy:

  • Design head-to-head comparison experiments:

    • Test multiple antibodies on identical samples

    • Include known positive controls (mouse liver tissue, HEK-293 cells)

    • Implement knockout/knockdown validation

  • Document performance metrics systematically

This methodological framework guides researchers through evidence-based selection of anti-SCML4 antibodies optimized for their specific experimental requirements .